Welcome to our dedicated page for Aptinyx news (Ticker: APTX), a resource for investors and traders seeking the latest updates and insights on Aptinyx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptinyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptinyx's position in the market.
Aptinyx Inc. (Nasdaq: APTX), a biopharmaceutical company focused on brain and nervous system disorders, announced participation in two investor conferences. Management will present at the BMO Prescription for Success Healthcare Conference on June 23, 2020, at 2:30 p.m. ET and the SVB Leerink CybeRx Series: 2nd Annual CNS Forum on June 24, 2020, at 1:15 p.m. ET. Live webcasts of the presentations will be available on their website, with replays archived for 30 days. Aptinyx is advancing therapies for chronic pain, PTSD, and Parkinson's-related cognitive impairment.
Aptinyx Inc. (Nasdaq: APTX) reported a net loss of $14.7 million for Q1 2020, a decrease from $16.7 million in Q1 2019. The company's cash balance stands at $121 million, sufficient to support operations into 2022. Enrollment in the Phase 2 study of NYX-783 for PTSD has reached over 90%, with data readout anticipated in late 2020. However, enrollment has been paused in three other Phase 2 studies due to COVID-19 disruptions. R&D expenses decreased to $11.1 million, while collaboration revenue was $0.8 million, slightly down from the previous year.
Summary not available.